RxDoctor Payments Data

Kyle Stephens, DO

Family Medicine · Ventura, CANPI 1205204518

Payments from drug & device makers

$2,330in general payments, 2019–2025

Across 107 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$427
  • Novo Nordisk$212
  • Edwards Lifesciences$190
  • Otsuka America Pharmaceutical, Inc.$165
  • Neotract Inc.$160
  • AbbVie$150
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,330100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,330 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$115,930
Medicare patients
254
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide110$191,517
EliquisApixaban62$71,724
JardianceEmpagliflozin27$44,417
OzempicSemaglutide32$38,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$24,591
XareltoRivaroxaban18$24,519
TrulicityDulaglutide17$22,064
Breo ElliptaFluticasone/Vilanterol35$20,460
Testosterone49$16,100
JanuviaSitagliptin Phosphate15$11,996
Rosuvastatin Calcium206$3,115
Metoprolol Succinate158$3,087
Losartan Potassium237$2,589
Levothyroxine Sodium174$2,310
SynthroidLevothyroxine Sodium29$2,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$212$230,161142 claims
PfizerEliquis$16$71,72462 claims
GSKTrelegy Ellipta, Breo Ellipta$102$45,05260 claims
Boehringer IngelheimJardiance$29$44,41727 claims
Johnson & JohnsonXarelto$45$24,51918 claims
Lilly USA, LLCTrulicity$144$22,06417 claims
MerckJanuvia$18$11,99615 claims
AbbVieSynthroid$150$2,30429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →